Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2003 02:15 ET | Source: Crucell N.V.

Crucell Announces Malaria Vaccine Program in Collaboration with New York University, Walter Reed Army Institute of Research and GlaxoSmithKline

LEIDEN, The Netherlands, Oct. 22, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that its vaccine candidate against malaria will undergo...
October 14, 2003 02:15 ET | Source: Crucell N.V.

Crucell and Gene Medicine Japan Initiate Manufacturing Partnership for Asia

LEIDEN, The Netherlands and KOBE, Japan, October 14, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and Japan-based Gene Medicine Japan, Inc. (GMJ) today...
October 13, 2003 02:36 ET | Source: Crucell N.V.

Crucell Announces Third Quarter 2003 Results

LEIDEN, The Netherlands, Oct. 13, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the third quarter of 2003....
September 25, 2003 02:19 ET | Source: Crucell N.V.

Crucell and Novavax Announce PER.C6(TM) Vaccine Manufacturing Services

LEIDEN, The Netherlands, Sept. 25, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and Novavax, Inc. (Nasdaq:NVAX) announced today that they have entered...
September 22, 2003 02:26 ET | Source: Crucell N.V.

Joint Crucell and Harvard Medical School Study Demonstrates the Potential of New Vaccine Delivery System for Diseases like HIV/AIDS

LEIDEN, NEW YORK, Sept. 21, 2003 (PRIMEZONE) -- Dutch biotechnology company, Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and Harvard Medical School presented results of a joint study of a novel HIV...
September 19, 2003 02:22 ET | Source: Crucell N.V.

Crucell to Present at 2003 UBS Global Life Sciences Conference

LEIDEN, The Netherlands, Sept. 19, 2003 (PRIMEZONE) -- Dutch biotechnology company, Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced that it is presenting at the 2003 UBS Global Life...
September 19, 2003 02:18 ET | Source: Crucell N.V.

Crucell -- DSM Biologics Alliance to Present New PER.C6(tm) Data at Biophex Conference on September 25, 2003

LEIDEN and GRONINGEN, The Netherlands, Sept. 19, 2003 (PRIMEZONE) -- Crucell (Euronext:CRXL) (Nasdaq:CRXL) and DSM Biologics announced today that Dr. Bram Bout, VP Protein Production of Crucell, will...
September 03, 2003 02:19 ET | Source: Crucell N.V.

Crucell and Kimron Veterinary Institute Announce Anticipated Approval of West Nile Veterinary Vaccine Early 2004

LEIDEN, The Netherlands, Sept. 03, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and Israeli Kimron Veterinary Institute announced today that they...
August 28, 2003 02:12 ET | Source: Crucell N.V.

Crucell Hires Redington, Inc. to Expand its Reach and Raise Awareness in the US Investment Community

LEIDEN, The Netherlands, Aug. 28, 2003 (PRIMEZONE) -- In an effort to expand its reach and raise awareness in the US investment community, Dutch biotechnology company Crucell N.V. (Euronext:CRXL)...
August 12, 2003 02:15 ET | Source: Crucell N.V.

Crucell and GeneMax Enter PER.C6 License Agreement in Gene Delivery Field to Advance Clinical Trial

LEIDEN, Netherlands, August 12, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and US-based GeneMax Corp. (OTCBB:GMXX) (Frankfurt:GX1) today announced that...